May 23, 2024 7:56am

Reiterating, “the cell and gene therapy sector continues to “recalibrate” its share pricing expectations and I do NOT think this adjustment is completely over.”

Who speaks out while standing in-front, beside and behind investors - RMi

A daily analytic discipline is constructed by period updates and specific warnings of emerging situations

Never leave an investor uninformed

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

I ain't do'in nothing today ... hoping (not a technical term) for a better session; so lets play through with no caddy advise and a wet course!

 

Thursday: The pre-open Dow futures are UP +0.17% or (+69 points), the S&P futures are UP +0.65% or (+34 points) as the Nasdaq futures are UP +1.06% or (+199 points)

Futures are up in Thursday’s pre-market,

European markets were slightly higher,

Asia-Pacific markets were mixed.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Futures rose on Thursday … after indexes dropped yesterday, Wednesday after minutes from the Fed’s May meeting fueled concerns over “sticky” inflation and fear that Fed policy may push off cuts.

  • Wednesday: The Dow closed DOWN -201.95 points or -0.51%, the S&P closed DOWN -14.40 points or -0.27% while the Nasdaq closed DOWN -31.08 points or -0.18%
  • Wednesday’s advance/decline line at the open ended with a positive close of 18 incliners, 15 decliners and 2 flats
  • Month to date: 9 positive and 7 negative closes

Economic Data Docket: May manufacturing and services PMI

 

Wednesday’s RegMed Investors (RMi) Closing Bell: “yesterday’s chutes became today’s ladders barely climbing. It’s an honor to be considered the “canary in the (sectors) coal mine”!  I devote my time to collection and analysis of information/intelligence to assist investors in the perception of sector vulnerabilities and strengths – it’s more than opinion, the facts and truth need to be recognized!” … https://www.regmedinvestors.com/articles/13471

 

Q2/24:  May – 9 positive and 7 negative closes

  • April - 16 negative and 6 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

 

Yet again, I am passing on forecasting the daily indications as futures roll-up, I am feeling more uncertainty of knowns and unknowns in the aftermarket fluctuated as the pre-open waits for the all-clear alarm, …  it is still a mix of ups, downs and just unknowns.

  • The aftermarket and pre-market were mixed,  some ups, many downs and a number of neutrals.

 

The BOTTOM LINE: Reiterating, “Investors should be cautious … as major indexes slipped lower.

  • However, brace for continued volatility, that exacerbates any moves with risk appetite suppressed as uncertainty pervades the sector.
  • “Don't chase the cell and gene therapy sector; especially with the Nasdaq extended.”
  • Short and non-sweet: SELL into STRENGTH – accumulate some “powder” i.e., cash!

 

I put hours of effort into creating a daily dose of reality to reporting, while leveraging my 40 years of experience analyzing the key market-moving events and distill that into a cogent outlook.

 

If playing through the golf course, pick your irons for short and long swings!

  • Some “strategists point to CBOE Volatility Index options data that signal higher demand for hedges against sudden market declines, at a time when the gauge has dropped to historically low levels.” <Yahoo Finance>

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • Never forget, one of my usual lines. “The sector is … still what it is, until it isn’t and even then, it doesn’t seem to be … that is after taking a deep breath and holding it.”
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.